Stay updated with breaking news from Acerus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cerus (NASDAQ:CERS – Get Rating) and Artivion (NYSE:AORT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership. Profitability This table compares Cerus and Artivion’s net margins, return on […]
Cerus (NASDAQ:CERS – Get Rating) announced its earnings results on Thursday. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03, MarketWatch Earnings reports. Cerus had a negative net margin of 41.55% and a negative return on equity of 63.31%. During the same period in the previous year, […]
Cerus (NASDAQ:CERS – Get Rating) will be releasing its earnings data after the market closes on Thursday, May 5th. Analysts expect Cerus to post earnings of ($0.10) per share for the quarter. Cerus has set its FY 2022 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this […]
StockNews.com assumed coverage on shares of Cerus (NASDAQ:CERS – Get Rating) in a note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Friday, February 25th. CERS stock traded […]
Cerus Co. (NASDAQ:CERS – Get Rating) was the recipient of unusually large options trading activity on Tuesday. Investors bought 2,772 call options on the company. This represents an increase of approximately 1,095% compared to the typical volume of 232 call options. Separately, Zacks Investment Research lowered shares of Cerus from a “buy” rating to a […]